Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Immutep ( (IMMP) ) has shared an update.
On May 15, 2025, Immutep announced promising results from its INSIGHT-003 trial, which evaluates a combination of eftilagimod alpha (efti), KEYTRUDA® (pembrolizumab), and chemotherapy in first-line non-small cell lung cancer (1L NSCLC). The trial achieved a 60.8% response rate and a 90.2% disease control rate, showing significant improvement over historical controls. The data highlights efti’s potential to become a new standard of care, especially for patients with PD-L1 expression below 50%, who represent a high unmet need. These results strengthen Immutep’s position in the immunotherapy market and could have positive implications for stakeholders.
The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep exhibits financial challenges typical of R&D-focused biotechnology companies, with ongoing losses and strong equity but significant cash burn. Technical analysis suggests positive market momentum, supporting a more optimistic outlook despite valuation concerns. The overall score reflects these mixed dynamics, balancing potential for innovation and growth against financial robustness and market conditions.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the field of Lymphocyte Activation Gene-3 (LAG-3) related therapeutics, aiming to stimulate or suppress the immune response. Immutep’s diverse product portfolio is designed to provide innovative treatment options for patients and maximize shareholder value.
Average Trading Volume: 278,777
Technical Sentiment Signal: Sell
Current Market Cap: $262M
For a thorough assessment of IMMP stock, go to TipRanks’ Stock Analysis page.